Search

Natco Pharma receives USFDA nod to market renal disease drug

Lanthanum carbonate is the salt formed by lanthanum (III) cations and carbonate anions.

Aug 16, 2017 08:34 IST
facebook IconTwitter IconWhatsapp Icon

Natco Pharma on 14 August 2017 announced that it has received approval from the US Food and Drug Administration (USFDA) to market Lanthanum Carbonate chewable tablets in various strengths.

The tablets are used in treatment of patients with End Stage Renal Disease (ESRD).

Natco’s Lanthanum Carbonate tablets are indicated to reduce serum phosphate in patients with end stage renal disease.

CA eBook

About Lanthanum Carbonate

Lanthanum carbonate is the salt formed by lanthanum (III) cations and carbonate anions.

It is an ore of lanthanum metal, along with monazite.

It is used in medicine as a phosphate binder. It is prescribed for the treatment of hyperphosphatemia, primarily in patients with chronic kidney disease.

About Natco Pharma

Natco Pharma Limited was incorporated in Hyderabad in the year 1981.

At present, the company has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.

The company is well recognized for its innovation in Pharmaceutical R&D.

Download our Current Affairs & GK app For exam preparation

डाउनलोड करें करेंट अफेयर्स ऐप एग्जाम की तैयारी के लिए

AndroidIOS